{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicyvfftyy3fg52e72u6xxitz4vvsje36xnuaq43wybdzdcqokinu4",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mkxmiofgo2y2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihkpeq7m3zhnwbmuf6tzte2bcpykiksq6zocj6fibq7k5zgz25pou"
    },
    "mimeType": "image/jpeg",
    "size": 520776
  },
  "path": "/news/2026-04-liquid-biopsy-response-breast-cancer.html",
  "publishedAt": "2026-05-03T11:00:03.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Immunotherapy has become a standard of care in treating high-risk, early-stage breast cancers, yet it has had limited success in shrinking tumors. New biomarkers that can improve outcomes for patients are urgently needed. Now, a study led by researchers at the Vanderbilt-Ingram Cancer Center has found that repeated blood sampling—essentially, a liquid biopsy—can assess and predict the evolving antitumor immune response to therapy.",
  "title": "Liquid biopsy predicts response to breast cancer immunotherapy"
}